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CO2 and gadopentetate dimeglumine as alternative contrast
agents for malfunctioning dialysis grafts and fistulas.
Background. Hemodialysis grafts and native fistulas are fre-
quently evaluated angiographically utilizing iodinated contrast
material to determine the cause of malfunction. Occasionally,
patients are not able to receive iodinated contrast material due to
a history of previous severe allergic reaction or concern that
iodinated contrast material could worsen renal function requiring
premature initiation of permanent dialysis. We set out to test the
feasibility of gadopentetate dimeglumine as an alternative con-
trast agent in conjunction with carbon dioxide (CO2) angiography
in the evaluation and treatment of hemodialysis grafts and native
fistulas in patients who have a contraindication to iodinated
contrast material.
Methods. Six patients with a malfunctioning hemodialysis graft
and native fistula were evaluated. Four patients were successfully
evaluated using carbon dioxide and gadopentetate dimeglumine.
Two additional patients underwent balloon angioplasty using
gadopentetate dimeglumine alone as the alternative contrast
agent.
Results. All six patients successfully were evaluated and treated
using gadopentetate dimeglumine either alone or as a supplement
to CO2 angiography. Five of these patients had lesions success-
fully treated using gadopentetate dimeglumine alone or in com-
bination with CO2 as the angiographic contrast agents. One
patient underwent a successful diagnostic angiogram using gado-
pentetate dimeglumine and CO2 as alternative contrast agents
and was subsequently treated with surgical revision. The gado-
pentetate dimeglumine angiograms identified the arterial anasto-
mosis and more clearly identified stenotic lesions and venous
outflow anatomy compared to carbon dioxide angiograms.
Conclusion. Gadopentetate dimeglumine is useful as an alter-
native contrast agent in conjunction with CO2 in patients with
malfunctioning hemodialysis grafts and fistulas, who have a con-
traindication to the administration of iodinated contrast material.
Contrast angiography has long been the definitive
method of choice for evaluating hemodialysis grafts in
native fistulas for the presence of underlying stenoses [1].
Once the lesions have been detected, percutaneous trans-
luminal angioplasty has also been used to successfully treat
flow reducing lesions in hemodialysis grafts and native
fistulas for more than 20 years [2]. In patients with a history
of a severe reaction to iodinated contrast material or
concern that contrast nephropathy could precipitate the
need for premature permanent dialysis in a patient with a
hemodialysis graft or native fistula placed in preparation
for future dialysis, a noniodinated contrast agent would be
preferable for hemodialysis fistulography. We describe a
technique to evaluate and subsequently treat malfunction-
ing hemodialysis grafts and fistulas in patients who have a
contraindication to the administration of iodinated contrast
material.
METHODS
Six patients with malfunctioning hemodialysis grafts or
fistulas and a contraindication to iodinated contrast mate-
rial underwent diagnostic fistulography. Five of these pa-
tients had lesions uncovered that were successfully treated
percutaneously. Four of the six patients were evaluated
with carbon dioxide (CO2) and gadopentetate dimeglumine
(Magnevest Berlex Laboratories, Wayne, NJ, USA) as
alternative contrast agents. No iodinated contrast agents
were used. The remaining two patients were treated per-
cutaneously using gadopentetate dimeglumine as the con-
trast agent following a previous diagnostic contrast arterio-
gram using iodinated contrast. Both of these patients
developed a significant reaction to iodinated contrast ma-
terial during the diagnostic examination requiring the
procedure to be terminated before completion and exclud-
ing further use of iodinated contrast material. Gado-
pentetate dimeglumine was used in these two patients as an
alternative contrast agent during the percutaneous treat-
ment.
Of the six patients studied, four patients (Patients 1, 2, 5
and 6) presented with decreased flow and increased venous
pressures within the hemodialysis graft or fistula. One
patient (Patient 4) presented with a clotted fistula. One
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patient (Patient 3) who had not yet begun hemodialysis, but
had a hemodialysis graft placed in anticipation for future
hemodialysis, presented with a decrease in the thrill within
the graft on physical examination.
Patients with a history of contrast reaction to iodinated
contrast material were studied in the following manner. If
the hemodialysis graft or native fistula was patent on
clinical examination, the patient was first studied using CO2
delivered via an angiocatheter placed in an antegrade
fashion in the arterial segment of either the hemodialysis
graft or outflow vein of the native fistula. CO2 was delivered
using a plastic bag delivery system (Angiodynamics, Glen
Falls, NY, USA) described by Hawkins, Caridi and Kerns
[3]. Initially, a gentle 10 cc injection of CO2 was adminis-
tered to evaluate the graft and venous outflow, and to
insure that reflux into the native artery did not occur.
Reflux into the native artery has been associated with
“neurologic sequella” including seizures in a previous study
[4]. This test injection was repeated with increasing 10 cc
increments of CO2 until adequate images of the graft and
venous outflow were obtained. This usually required an
injection of approximately 30 ccs of CO2 for each station of
the arteriogram. In each of the four patients that a CO2
angiogram was performed, a 30 cc injection demonstrated
the graft and/or venous anastomosis, the remainder of the
venous outflow and the central veins without evidence of
reflux into the native inflow arteries (Fig. 1A). CO2 was not
used to evaluate the arterial anastomosis. In addition, CO2
injections were not initially performed in the patient with
an occluded hemodialysis graft (Patient 4) due to concerns
that the CO2 may reflux into the native artery.
The arterial anastomosis was evaluated using a “reflux”
technique. A blood pressure cuff was placed at the level of
the mid humerus and inflated into a pressure of 20 to 30
mm Hg greater than the peak systolic pressure. Digital
subtraction angiograms (DSA) were then performed using
6 to 10 ccs of full strength gadopentetate dimeglumine
injected by hand (Fig. 1B). Gadopentetate dimeglumine
was then used to evaluate areas of suspected hemodynam-
ically significant stenosis visualized on the CO2 angiograms
because CO2 angiograms have been shown to overestimate
the degree of stenoses in dialysis fistulas (Fig. 1C) [4].
In patients with a hemodynamically significant stenosis,
percutaneous balloon angioplasty was performed. In pa-
tients with a history of a severe reaction to iodinated
contrast material, the angioplasty balloon was filled with a
2/3rd strength mixture of gadopentetate dimeglumine (di-
luted with saline) in the event of balloon rupture. Angio-
plasty results were monitored with CO2 angiography and
final results confirmed with DSA performed with a hand
injection of 6 to 8 cc of full strength gadopentetate dime-
glumine.
In the patient with an occluded hemodialysis graft, 1 to 2
cc of full strength gadopentetate dimeglumine was injected
to confirm the presence of a clotted fistula. The graft was
declotted mechanically using a percutaneous thrombolytic
device (Arrow Percutaneous Thrombectomy Device; Ar-
row International, Reading, PA, USA) and a #3 Fogarty
balloon catheter (Baxter Inc., Irvine, CA, USA). The
venous anastomotic stenosis was subsequently treated with
balloon angioplasty. Digital subtraction angiograms were
performed to monitor the progress of the intervention
using hand injections of 2 to 6 ccs of gadopentetate
dimeglumine.
RESULTS
Abnormalities were detected in all six patients (4 patients
studied using carbon dioxide and gadopentetate dimeglu-
mine, and 2 patients studied using gadopentetate dimeglu-
mine after an earlier attempt to perform a diagnostic
angiogram could not be completed due to a contrast
reaction to iodinated contrast material; Table 1). In the
four patients evaluated with carbon dioxide and gado-
pentetate dimeglumine, the gadopentetate dimeglumine
was helpful in better evaluating areas of suspected stenoses
in Patients 1 and 2, better identified venous out flow in
Patient 3, and was used in place of CO2 in Patient 4 because
of concerns that CO2 might reflux into the native artery in
this patient with an occluded graft. Gadopentetate dime-
glumine was used successfully to evaluate the arterial
anastomosis in all four patients.
In Patient 1, a moderate to severe stenosis in the venous
limb of the graft identified on the CO2 angiogram (Fig. 1A)
did not appear to be as significant on the gadopentetate
dimeglumine angiogram (Fig. 1C). In Patient 2 with a
native fistula, CO2 angiography demonstrated a diffusely
diseased venous outflow in the forearm with a high grade
stenosis just peripheral to the elbow. A gadopentetate
dimeglumine angiogram demonstrated high grade stenosis
just peripheral to the elbow, but showed the remainder of
the venous outflow in the forearm to be patent without
additional focal stenoses. (Fig. 2 A, B). In Patient 3, the
CO2 angiogram demonstrated an occlusion of the venous
outflow at the level of the elbow and lower humerus,
however, the venous anatomy at the level of the elbow and
humerus was not well identified. The DSA performed with
gadopentetate dimeglumine better visualized the site of
occlusion, numerous venous collaterals, and existing patent
deep and superficial venous outflow veins.
In the two patients who were unable to have their studies
completed with iodinated contrast material (Patients 5 and
6) due to contrast reaction, the abnormality identified on
the iodinated contrast examination was confirmed with
gadopentetate dimeglumine and successfully treated with
percutaneous balloon angioplasty. Satisfactory post-angio-
plasty results were demonstrated with gadopentetate dime-
glumine angiograms.
At the conclusion of each of the five interventional
procedures, an excellent thrill was present. In the one
patient with renal insufficiency who had not yet begun
hemodialysis (Patient 3), the serum creatinine remained
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Fig. 1. (A) Carbon dioxide angiogram in patient Number 2 demonstrates a hemodialysis PTFE loop graft. At the level of the forearm loop and venous
anastomosis (arrow), a high grade stenosis at the venous anastomosis and moderate focal narrowing within the limb of the graft (open arrow) is seen.
(B) Gadopentetate dimeglumine demonstrates the arterial anastomosis (arrow).
stable at 3.9 mg/dl at 48 hours post procedure. Each of the
remaining patients was successfully dialyzed without com-
plication within 24 hours of the procedure.
The range of gadolinium volumes administered was
between 24 to 60 cc, with an average volume of approxi-
mately 37 cc. There were no complications in any of the six
patients during the procedure or the interval period up to
dialysis treatment.
DISCUSSION
Contrast angiography is considered the method of choice
for evaluating malfunctioning dialysis grafts and fistulas [1,




type Indications for alternative agent Clinical indication for study
Gd dose
cc Results
1 34/M Fistula H/O anaphylaxis with previous contrast
examination
Increased venous pressures on dialysis 28 cc PTA venous outflow
lesion/successful
2 62/F Graft Laryneal edema during previous contrast
study
Increased venous pressures on dialysis 24 cc PTA venous
anastomosis/successful
3 47/M Graft Renal insufficiency, dialysis not yet
initiated
Decreased thrill on P.E. 28 cc Surgical revision
4 42/M Graft History of H/O anaphylaxis with previous
contrast examination
Clotted dialysis graft on P.E. 38 cc Graft declotted, PTA
venous anastomosis/
successful
5 24/F Graft Hives, severe pruritis during diagnostic
fistulagram
Increased venous pressures on dialysis 45 cc PTA venous
anastomosis/successful
6 74/F Graft Hypotension, tachycardia, hypoxia during
diagnostic fistulagram
Increased venous pressures on dialysis 60 cc PTA venous
anastomosis/successful
Definitions are: graft, upper extremity PTFE graft; fistula, native fistula that is, a Brescia 5 Cimino fistula; H/O, history of.
Fig. 1. Continued. (C) Gadopentetate dimeglumine angiogram obtained with a hand injection of 8 ccs. This study confirms the high-grade stenosis at
the venous anastomosis seen in panel A (arrow). The area of moderate narrowing within the venous limb of the graft identified on the CO2 angiogram
in panel B (open arrow) does not appear as significant on the Gadopentetate dimeglumine study (curved arrow).
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5]. A small number of patients with hemodialysis grafts or
fistulas requiring contrast angiography have a history of a
serious contrast reaction. Although uncommon, serious
reactions to iodinated contrast have been reported in 1 in
40,000 to 250,000 examinations [6–8]. Minor adverse reac-
tions are more frequent and have been reported to occur in
approximately 12 to 13% of patients receiving iodinated
contrast agents [6].
Recent improvements in CO2 imaging and delivery have
resulted in an increased interest in the use of CO2 as an
alternative intravascular contrast agent in patients with
life-threatening reactions to iodinated contrast material or
history of renal insufficiency. However, when used to
evaluate hemodialysis grafts and fistulas, CO2 consistently
overestimated severity of stenoses when compared to io-
dinated contrast material [4]. In addition, the arterial
anastomosis was not able to be adequately evaluated
because of three episodes of “neurologic sequella” in five
patients in whom CO2 was “refluxed” into the arterial
anastomosis and native artery.
Recent reports have described the use of gadopentetate
dimeglumine for angiographic studies of the abdominal
aorta, mesenteric vessels, pelvis, peripheral vasculature and
renal arteries [9–11]. Gadolinium has an atomic number of
64 and a K-edge of 50.2. Although gadolinium has been
shown to absorb sufficient energy to be visualized with
Fig. 2. (A) CO2 angiogram of the venous outflow of a hemodialysis native fistula in patient Number 1 demonstrates bubbling of CO2 within several
pseudoaneurysms (arrow) and an apparently poor venous outflow conduit (open arrows). (B) Gadopentetate dimeglumine angiogram demonstrates a
satisfactory outflow venous conduit (curved arrows) with a focal high grade stenosis present (arrow).
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DSA, image quality with gadolinium is inferior to iodinated
contrast material [9, 10]. The inferior image quality when
using gadopentetate dimeglumine as an angiographic con-
trast agent compared with iodinated contrast material is
due to the low concentration of gadolinium in the commer-
cially prepared gadolinium contrast agents (0.5 mol/liter)
The maximum dosage of gadopentetate dimeglumine ad-
ministered to each of the six patients was less than 0.3
mmol/kg. Doses up to 0.4 mmol/kg have been used safely in
patients without evidence of nephrotoxicity or significant
systemic toxicity [12–14]. There have been no reports of
cross-reactivity between gadolinium based contrast agents
and iodinated contrast agents in patients in patients with a
history of allergic reaction to iodinated contrast material.
However, although extremely rare, severe, idiosyncratic
antiphylactic reactions to gadolinium have been reported
[15].
In patients undergoing hemodialysis, gadopentetate
dimeglumine has been shown to be easily eliminated.
Seventy percent of the gadopentetate dimeglumine is elim-
inated from the plasma during a three hour dialysis session.
Approximately 97% of the initial dose is eliminated after
three dialysis sessions [16]. In addition, patients on hemo-
dialysis were not at greater risk for an increased incidence
of side effects, electrolyte abnormalities, or serum creati-
nine elevations following administration of gadopentetate
dimeglumine [13, 16].
The use of gadopentetate dimeglumine is limited by the
total dose that the patient can receive. In addition, the cost
of the gadopentetate dimeglumine is considerable and is in
the range of approximately three to five times the cost of
low osmolarity contrast material.
Despite the disadvantages of cost and limited volumes
that can be delivered to the patient, gadopentetate dime-
glumine may have selective applications for use in patients
with hemodialysis grafts or native fistulas and a history of
severe reaction to iodinated contrast material, or in pa-
tients with malfunctioning hemodialysis grafts or native
fistulas with renal insufficiency who have not yet begun
dialysis. In these patients, gadopentetate dimeglumine can
be used in to supplement carbon dioxide angiographic
techniques to confirm stenoses, evaluate the arterial anas-
tomosis, and monitor the progress of interventional therapy
during evaluation and treatment of malfunctioning hemo-
dialysis grafts and fistulas.
In conclusion, gadopentetate dimeglumine in conjunc-
tion with carbon dioxide angiography can be helpful in
evaluating and treating malfunctioning hemodialysis grafts
or native fistulas in patients who have a contraindication to
iodinated contrast material.
Reprint requests to David J. Spinosa, M.D., Department of Radiology, Box
170, University of Virginia Health Sciences Center, Charlottesville, Virginia
22908, USA.
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